Mumbai: Global pharma major Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...

The research suggests that liraglutide, a drug originally developed for diabetes (Victoza) and weight management (Saxenda), may significantly reduce the frequency of debilitating migraine.

Lupin receives USFDA approval for generic diabetes medications, including Liraglutide Injection and Glucagon for Injection.

A new study found that GLP-1 weight-loss drugs with the active ingredient liraglutide can significantly reduce migraines.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Liraglutide, the glucagon-like peptide-1 receptor agonist sold by Novo Nordisk as Victoza, had been shown to boost glycemic control and promote weight loss in T1D patients over a 12-week period, ...

In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...

The liraglutide group also showed greater improvements in glycated hemoglobin level, plasma glucose level, and other measures of glucose control. Furthermore, ...

We measured liraglutide in plasma and CSF with a radioimmunoassay specific for the N-terminus of the GLP-1 moiety of liraglutide. Mean plasma liraglutide was 31 (range: 21–63) nmol l−1.